| Program | Indications | Discovery | Preclinical | Phase 1a | Phase 1b/2 |
|---|---|---|---|---|---|
| EP262 MRGPRX2 Antagonist |
Chronic Inducible Urticaria (CIndU) | ||||
| Chronic Spontaneous Urticaria (CSU) | |||||
| Atopic Dermatitis (AD) | |||||
| Other Indications | |||||
| EP547 MRGPRX4 Antagonist |
Cholestatic Pruritus (CP) | ||||
| Uremic Pruritus (UP) | |||||
| Other Indications | |||||
| MRGPRD | Undisclosed | ||||
| MRGPRX1 | Undisclosed | ||||
| MRGPRX2 Antagonist (EP262) | |||
| Discovery | Preclinical | Phase 1a | Phase 1b/2 | Chronic Inducible Urticaria (CIndU) |
Chronic Spontaneous Urticaria (CSU) | |||
Atopic Dermatitis (AD) | |||
Other Indications | |||
| MRGPRX4 Antagonist (EP547) | |||
| Discovery | Preclinical | Phase 1a | Phase 1b/2 | Cholestatic Pruritus (CP) |
Uremic Pruritus (UP) | |||
Other Indications | |||
| MRGPRD | |||
| Discovery | Preclinical | Phase 1a | Phase 1b/2 | Undisclosed |
| X1 | |||
| Discovery | Preclinical | Phase 1a | Phase 1b/2 | Undisclosed |
All of Escient’s programs are wholly-owned.